Introduction
The high efficacy of the transferrin endocytosis process has tempted many investigators to ask whether this pathway could be exploited for the targeted delivery of drugs or larger molecules into cells. The first part of this article reviews the delivery of drugs and toxin proteins. A series of successful application in vitro and in vivo have been described. The use of toxin proteins appears particularly advantageous because the successful delivery of one to two toxin molecules to the cytoplasm may kill a cell, thereby providing a most sensitive test system which is essential for further improvement of the delivery systems. Recent advances in molecular biology have also supplied sensitive detection methods to assess gene transfer techniques. The major part of this review discusses the use of the transferrin uptake pathway for the delivery of genes into cells. This concept may broaden the range of applications, as genes may be designed to have either a cytotoxic or a biologically curative effect on cells, and the gene products may be produced in numerous copies over an extended period. The first section describing the natural role of transferrin has been kept short; extensive reviews on the structure and physiology of transferrin and the transferrin receptor can be found elsewhere [1] [2] [3] .
Physiology of transferrin and transferrin receptor

Transferrin (Tf) and transferrin receptor ( TfR )
Transferrin (Tf) is an abundant serum component with the capacity to bind and transport iron. The main function of this 80-kDa glycoprotein [4, 5] consists of providing cells with iron which they need in the process of DNA synthesis for the activity of ribonucleotide reductase, and for specialized functions (synthesis of hemoglobin in reticulocytes; iron transport to the fetus in syncytial trophoblasts). Iron is supplied to cells by attachment of iron-loaded Tf to its specific cell surface receptor followed by receptor-mediated endocytosis, a process that efficiently internalizes receptorbound transferrin into cells. The transferrin receptor, a dimeric transmembrane glycoprotein of 180 kDa [6, 7] , is present on the surface of most proliferating higher eukaryotic cells [8, 9] . Erythroblasts express particularly elevated numbers of up to 800 000 TfR per cell. Proliferating TfR-expres-sing tissues include bone marrow, intestinal epithelium, and epidermis, but expression is also found in a few non-proliferating tissues such as hepatocytes, tissue macrophages, pituitary cells, pancreas islet cells, or the endothelium of brain capillaries. Tumor cells frequently carry elevated numbers of TfR compared with the corresponding normal cells. In tumor-bearing patients reduced serum levels of Tf are often observed. 115 2 x 104 Tf molecules internalized per minute per cell [13] . A second, minor pathway with a longer transit time has been identified as routing to the trans-Golgi and then back to the plasma membrane [14a] . It also should be kept in mind that modification of Tf, crosslinking the receptor (e.g. by the use of antibodies or multivalent ligands [14b] ) and/or lysosomotropic agents may strongly influence the intracellular fate of Tf.
Receptor-mediated endocytosis and the intracellular cycle
Receptor-mediated endocytosis is a natural process which cells utilize for the uptake of protein or peptides such as low-density lipoprotein, asialoglycoproteins, epidermal growth factor, transferrin, insulin, and small vitamins such as folic acid. Many viruses also gain entry to cells via receptor-mediated endocytosis. The first steps in this process include binding of the ligand to specific cell-surface receptors, receptor clustering and internalization through coated vesicles into endosomal acidic compartments. The subsequent pathways are strongly dependent on the type of receptor/ligand pair; the low endosomal pH may or may not trigger dissociation of receptor and ligand, and sorting processes may lead to degradative lysosomal compartments.
The receptor-mediated endocytosis process of Tf differs from other ligand/receptor pairs in several respects. After internalization, iron-loaded Tf releases the iron at the low endosomal pH, while apoTf (iron-free Tf) remains bound to the receptor. The receptor-apoTf complex is sorted into exocytic vesicles back to the cell surface, where apoTf has ca. 30-fold lower affinity for the TfR at the extracellular pH and is released into the medium. Whether iron-loading is necessary for the uptake of Tf-conjugates, has not been tested. (With polyvalent Tf conjugates, such as described in Sect. 4.4, iron-loading is no strict requirement [our unpublished observation].) The entire Tf cycle [10] [11] [12] may take only 4-5 min (as shown in K562 cells with ca. 150 000 TfR per cell) with a mean transit time of about 10 min and avoids lysosomal compartments. The rapid recycling leads to very high turnover numbers on the order of 3.Targeted delivery of drugs, proteins and toxins via the transferrin receptor
Tf and TfR conjugates for improved uptake into cells
Many low-molecular-weight, pharmacologically active compounds are readily taken up into cells by passive diffusion processes through the cell membrane, whereas the uptake of charged molecules or larger compounds such as peptides, proteins, or nucleic acids is restricted. Moreover, for several therapeutic applications the specific targeting of a subset of cells is desired. A great deal of data accumulated during the last decade demonstrate that the TfR-mediated endocytosis pathway may be exploited to solve both tasks, namely enhanced intracellular uptake as well as targeted delivery of biologically active compounds. Low-molecular-weight drugs, protein toxins, or larger structures such as liposomes or minibeads have been linked to Tf or to antiTfR antibodies (see Table 1 ). The linkages were produced by a wide variety of chemical conjugation procedures or by the generation of chimeric antiTfR fusion proteins.
The targeting of drugs or toxins to tumor cells by specific antibodies has long been a topic of interest [15] . Using monoclonal antibodies generated by immunizations with neoplastic cells, Trowbridge and Omary [8] and Sutherland and colleagues [9] identified the transferrin receptor as a major cell surface protein in proliferating cells. Based on this discovery, Trowbridge and Domingo synthesized antiTfR antibody conjugates of the plant toxin ricin A or the bacterial diphtheria tox- 1989 76 1990 in A subunit [27] . These conjugates displayed effective killing of human tumor cells in vitro at concentrations up to 1000-fold lower than using the antibody combined with the non-coupled toxin fragments alone. Tumor growth inhibition was also found in a melanoma in vivo model in nude mice; however, in these experiments unmodified antibody also mediated growth inhibition to a similar extent (see also antitumor activity of antiTfR antibodies described in Refs. 85 88) . Moreover, in these early experiments, the pathway by which the TfR-bound toxins enter the cells was not characterized. During studies aimed at the elucidation of the cellular uptake of iron, Takahashi and Tavassoli demonstrated that the iron uptake pathway can be subverted for the delivery of 345-nm minibeads linked to Tf into cellular vesicles of leukemia cells or reticulocytes [71] . In the same year Pastan and colleagues described the delivery of Pseudomonas exotoxin-antiTfR antibody conjugates into cellular endosomes [49] . Subsequent stu-dies have confirmed that the Tf delivery pathway is very flexible in accommodating transport of both small drugs [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , such as adriamycin, and structures [72] [73] [74] [75] [76] such as Tf-coated liposomes.
Investigations with TfR-binding toxin conjugates and other immunotoxins had shown that despite efficient and specific receptor-mediated endocytosis the cytotoxicities were variable and often too low to be of therapeutic interest. Often natural toxins consist of two polypeptide chains. The A-chain contains the activity that inhibits the protein synthesis of the target cell, and the B-chain contains functions that trigger uptake into cellular vesicles and translocation of the A-chain to the cytosol. In the construction of immunotoxins the B-chain often has been replaced by a ligand such as Tf or ~TfR, resulting in enhanced target cell specificity but also loss of the mechanism for translocation to the cytosol. As a consequence, the limiting step in making immunotoxins available for their intracellular action seemed to be the transport of the toxin part from the vesicular compartment to its target.
Several strategies have been reported to enhance the delivery and potency of TfR-targeted toxin conjugates. Pastan and colleagues had shown evidence that adenovirus, after receptormediated endocytosis, escapes into the cytoplasm by disrupting the endosome, thereby liberating other substances contained in the same vesicle [77] . Consistent with the idea that this disruption process may release immunotoxins from internal vesicles, the toxicity of Pseudomonas exotoxin conjugated to antiTfR or EGF was enhanced by the presence of adenovirus by up to 300-fold [49] or 10 000-fold [77] . The enhancing activity appeared to reside in the protein coat of the virus. Antibodies against adenoviral penton base blocked the enhancing activity without affecting virus uptake, suggesting that the penton base is important in endosomolysis [78] .
A series of basic, proton-binding substances that influence intracellular routing of endocytosed materials also potentiate the action of immunotoxins, such as the lysosomotropic agents ammonium chloride [36] , amines [79] and chloroquine [59, 66] , in addition to some lipophilic carboxylic ionophores (monensin, nigericin), and calcium channel blockers (verapamil [50] [51] [52] , diltiazem [52] , nifedipine). In particular, monensin has been shown to strongly enhance the cytotoxicity of immunotoxins such as TfR-targeted ricin A or methotrexate as described by Raso and colleagues [25, 30, 32, 34, 38, 42] and other groups [35, 39, 41, 65] . The mechanism of action of monensin in this process is not clear. Monensin catalyzes cation exchange across lipid bilayers. It has the capacity to transport protons across the endosomal membranes, thereby altering the pH. However, the potentiating effect on the action of immunotoxins exists at relatively low concentrations of monensin that do not affect endosomal pH, and it seems that mechanisms that alter intracellular trafficking are involved [41] . For example, monensin has been reported to cause accumulation of transferrin in perinuclear vesicular compartments, whereas chloroquine does not show this effect [14] . Another frequently made observation is that, depending on the toxin conjugate, the different lysosomotropic agents have differential effects. Ammonium chloride was found to enhance toxicity of immunotoxins such as an antiTfR-linked ricin A conjugate [36] whereas the cytotoxic activity of a Tfconjugated diphtheria toxin protein [43] was abolished by ammonium chloride. Presumably in the latter case the pH-triggered translocation of the DT A-chain mediated by the B-chain had been blocked.
Further approaches in immunotoxin delivery benefit from the efficient natural process by which the B-chain specifically assists translocation of the A-chain. For this purpose antibody conjugates of toxins have been prepared containing a "blocked" B-chain with reduced cell-surface binding. Diphtheria toxin mutants and conjugates thereof have been described by Youle and coworkers [44, 80] . CRM 107 has 10 000-fold lower toxicity and 8 000-fold lower binding activity relative to native DT; conjugation to Tf reconstituted full activity. Moreover, the Tf-conjugate, unlike native DT, was also highly toxic to murine cells. Pastan and co-workers [54] constructed the targetcell-specific immunotoxin antiTfR-LysPE40 by conjugation of antiTfR antibodies with recombinant 40-kDa fragments of Pseudomonas exotoxin that lack its cell-binding domain.
The mode of chemical conjugation in the preparation of immunotoxins creates additional complexities in the evaluation of biological effects. Different linkages containing reducible disulfide bonds, non-reducible linkages such as thioethers [36] , or acid-sensitive linkages [46, 81] have been found to possess different biological behaviour. Moreover chemical cross-linking procedure rarely are site-specific and often produce heterogeneous products, also containing multiple cross-links. Recent developments that present elegant alternatives to chemical conjugation are applications where the conjugate consists exclusively of protein or peptide components. The Pastan group has generated several recombinant immunotoxins containing the truncated toxins PE40 or DT388 linked to single-chain versions of the variable antibody domain directed at the IL-2 receptor [82, 83] or the TfR [48] . Comparison of chemical conjugates (antiTfR-LysPE40) with the corresponding fusion protein showed a 750-fold higher activity of the recombinant fusion protein. Similar findings have been made by Youle and colleagues who described a recombinant cytotoxic antiTfR RNase fusion protein [69] which is 1000-fold more active than the corresponding chemically linked RNase hybrids [67, 68] . Instead of using conventional immunogenic bacterial or plant toxins, the investigators converted a human serum RNase, angiogenin, into an immunotoxin by generating a fusion gene of angiogenin with a humanized antiTfR antibody heavy chain; expression in chimeric cells that secrete the light chain of the same antibody results in the formation of the antibodyangiogenin fusion protein.
Targeting to various cell types via the transferrin receptor
The constitutive expression of TfR is found in proliferating tissues such as the bone marrow, epidermis and intestinal epithelium, and, to a lesser extent, in non-proliferating tissues such as hepatocytes or macrophages. The TfR levels in proliferating malignant cells have often been found to be far higher than in the corresponding normal cells. The increased receptor levels result from changes in both proliferation and differentiation: i.e., TfR numbers in transformed cells are far higher than in non-proliferating cells and may be more than twice as high as in the corresponding normal cells even when proliferating at the same rate [84] . As internalization rates and intracellular routing of TfR are similar to that which occurs in normal cells [84] , an overall enhanced rate of Tf endocytosis is observed. For these reasons the TfR has been proposed as a target for cancer therapy [85] . Trowbridge and colleagues used monoclonal antiTfR antibodies to inhibit cell growth in vitro [86-87b] and in vivo [27, 88] in some tumor systems. Other groups have shown that Tf-gallium complexes [89] , the active form of the chemotherapeutic drug gallium nitrate, or Tf-indium complexes [90] inhibit growth of leukemic cells. The TfR-mediated delivery of toxins (see above, Sect. 3.1) has proven to be particularly effective in specifically killing TfR-expressing tumor cells in vitro. In order to demonstrate a potential applicability for therapy, TfR-targeted immunotoxins have been tested in several animal model systems. A human ovarian cancer model, where the malignant cells grow intraperitoneally as ascites in nude mice, has been used by Pastan and colleagues. They demonstrated that antiTfR-PE conjugates injected intraperitoneally are able to kill the ovarian cancer cells in the peritoneal cavity and prolong the survival of mice to 100 days or longer [53] . However, extraperitoneal cancer cells were not affected by the immunotoxin. In similar models for human mesothelioma or colorectal carcinoma Griffin and Raso [32, 42] tested the effect of ricin A-antiTfR immunotoxin in intraperitoneal tumor xenografts in nude mice. Co-administration of monensin/lipid emulsion was essential for the antitumor effect. Prolonged survival of mice with advanced macroscopic intraperitoneal tumors and cure in 40% of mice with microscopic intraperitoneal tumors was observed.
Immunotoxins containing anti-murine TfR antibodies have been applied in a syngeneic peritoneal lymphoid tumor model [33] . McIntyre and co-workers reported activity of an antiTfR-gelonin conjugate against Burkitt's lymphoma neografts in nude mice upon direct intratumoral administration into subcutaneous nodules, or intravenous administration at the time of intraperito-neal tumor inoculation [57] . Established solid CEM tumors have been shown to completely regress upon intratumoral injection of whole ricinantiTfR antibody conjugates [37] . Intraperitoneal administration of adriamycin-antiTfR antibody conjugates [21, 22] significantly inhibited the growth of subcutaneous solid B-lymphoma xenografts in nude mice. The use of Tf-adriamycin in a preliminary clinical study in acute leukemia patients has been reported [17] . A promising further application in vivo has been reported using the immunotoxin antiTfR-LysPE40, where intraperitoneal administration caused regression of subcutaneous A431 tumors [54] .
Targeting via the TfR may also allow delivery of compounds into brain tissues where access is restricted by the blood/brain barrier. Jefferies and colleagues [91] discovered that after injection into the blood, monoclonal antibodies against the TfR labeled the endothelium of brain capillaries but not of other tissues. Further studies showed binding, endocytosis and transcytosis of iodine-labeled Tf by brain capillaries [92, 93] . Only 20% of Tf was found to be recycled whereas approximately 50% was transcytosed into the brain parenchyma. The tight brain capillary wall is devoid of intercellular gaps or channels that exist in other endothelial layers, and delivery of hydrophilic compounds by processes such as passive diffusion is prevented. The presence of specific transport systems for transferrin, insulin [94] , amino acids or glucose in the capillary endothelial cell layer therefore seems to be important for providing the brain with nutrients. Recently, several groups have started to use the special transport activity of brain capillaries for the delivery of drugs, peptides, or antisense oligonucleotides to the brain [for review, see Ref. 95] . In order to exploit the Tf transcytosis pathway, Friden and colleagues prepared a conjugate between the antiTfR antibody OX-26 and methotrexate [26, 96] . The conjugates, when injected intravenously into rats, were targeted to the brain capillaries where after 30 min the drug had accumulated to levels ca. 50-fold higher than unconjugated drug. After a further 24 hours the majority of the drug was found in the brain parenchyma fraction which is consistent with a transcytosis event. Since major distribution to other tissues will also occur, the delivery of relatively toxic compounds to the brain using antiTfR antibodies seems not generally applicable.
Data like those reviewed in this article give accumulating evidence that Tf or antiTfR antibodies are attractive candidates for the delivery of drugs or toxin proteins that are cytotoxic at very low doses; for example, one to two ricin A molecules are able to kill a cell. However, it is not yet proven whether by the use of Tf or antiTfR antibodies a sufficiently high targeting specificity can be obtained that would be required to avoid systemic toxicity (e.g. in the liver and bone marrow). The approach also suffers from the fact that many of the conjugates are highly immunogenic. Humanization of toxin conjugates is one approach to overcome this drawback [69] . Alternative ways may include receptor-mediated delivery of genes that express toxins or other therapeutic proteins (see below) under the control of tissue-or tumorspecific promoter elements, for intracellular generation of these protein within the target cells, thus avoiding some of the immune system exposure and systemic toxicity.
Transferrin-receptor-mediated gene transfer
Viral and non-viral gene transfer methods
The delivery of nucleic acids and expression of the contained genes in eukaryotic cells is a topic of increasing interest in molecular and cellular biology as well as in medicine [97, 98] . Recombinant viral vectors with high gene transfer efficiency such as retroviral [99, 100] , vaccinia virus [101, 102] , adenovirus [103, 104] and adenovirus-associated virus [105, 106] have been developed in which part of the viral genome has been replaced by a gene to be introduced into eukaryotic cells. These vectors, however, can be limited in their cell tropism, in the size of the gene to be introduced, in the compatibility of the introduced DNA with viral replication, and the toxicity to the cells (e.g. vaccinia virus).
During the last 30 years non-viral gene transfer methods have been elaborated using nucleic acids associated with basic proteins [107, 108] , cationic polymers such as DEAE-dextran [109, 110] , polyornithine [111] , polybrene [112] , calcium phosphate precipitates [113] [114] [115] , liposomes [116] [117] [118] , cationic lipids [119, 120] , lipopolyamines [121, 122] , or electroporation [123, 124] and microinjection [125] . General reviews are given by Felgner [126] and Cotten and Wagner [181] . These gene transfer techniques, although still not reaching the efficiencies of viral vectors, have the advantage of being very flexible with regard to the type and size of nucleic acid to be transported. Most importantly, the provision of synthetic gene-transfer vehicles with components that mediate specific binding to cellular receptors, endocytosis, and delivery to the nucleus of the cell may lead to improved gene transfer systems with broad applicability. Recent developments (see below) have demonstrated that receptor-mediated endocytosis pathways can be adopted for the delivery of DNA into eukaryotic cells.
Receptor-mediated endocytosis of transferrin DNA complexes
More than 10 years ago the first reports were published [127, 128] describing the concept of exploiting natural endocytosis pathways of protein ligands for the delivery of DNA macromolecules. At that time it was far from obvious that the cellular endocytosis process of rather small proteins may be subverted for the uptake of large (up to several hundred nanometers) DNA particles. Subsequent studies on the TfR-mediated endocytosis pathway showed that coupling of Tf to 350 nm or 50 nm latex minibeads [71, 72] or to liposomes [72] does not affect the cellular uptake and biological activity of Tf in L1210 leukemia cells, rat reticulocytes, or leukemic LzC cells. Pastan and co-workers suggested the delivery of DNA to cells by covalent linkages to protein ligands such as ~2-macroglobulin [127] . More recently, based on this idea, Tf-DNA conjugates were prepared [129] which were found to bind TfR on rabbit bone marrow cells. Alternative approaches use compositions containing DNA associated with the protein-ligand in non-covalent mode. Stavridis and colleagues presented two ways of generating noncovalent linkages. Firstly, they showed evidence that Tf-coated liposomes containing labeled DNA [130] or DNA with the [3-8-globin gene associated with non-histone chromosomal proteins [131] were bound and partially internalized by rabbit erythroblasts after intravenous injection into rabbits. Similar liposomes coated with other ligands for cellular binding have been successfully used for gene delivery and expression by other groups [132, 133] . In a second approach presented by the group of Stavridis, the interaction of DNA with histones was utilized and complexes of tritium-labeled rabbit liver DNA and transferrin crosslinked to calf thymus histones were prepared [128] . These complexes were preferentially transported onto erythroblasts and reticulocytes in animal experiments. However, no data have been published demonstrating the uptake and expression of a gene using this system.
In order to generate well-defined DNA-binding ligands for receptor-mediated gene transfer, Ariatti and colleagues [134] suggested using proteins (such as transferrin and asialoglycoprotein) modified with positively charged N-acylurea groups that enable electrostatic binding to DNA [135] . N-Acylurea-modified transferrin was shown to be internalized by HeLa cells [136] . Although there are no published data on gene transfer using Nacylurea transferrin as ligand, successful gene transfer and expression of a CAT marker plasmid was demonstrated using insulin conjugated to Nacylurea albumin with the insulin serving as cell binding ligand and the N-acylurea binding the DNA [137] . A related approach developed by Wu and colleagues employs conjugates of asialo-orosomucoid and high-molecular-weight cationic poly(t,)lysine. Complexes of these DNA-binding conjugates with DNA plasmids encoding CAT marker genes or therapeutically relevant genes were shown to result in gene expression both in vitro in cultured HepG2 hepatoma cells [138, 139] and in vivo in the liver of rats or rabbits [140] [141] [142] [143] [144] .
Using conjugates of human Tf or the avian homologue of Tf, conalbumin, with the polycations protamine or polylysine acting as the DNAbinding moieties, Birnstiel and colleagues [145] found efficient transferrin-dependent receptormediated delivery and expression of luciferase marker genes (see Fig. 1 ) in avian HD3 and hu- man K562 erythroid cell cultures [146, 147] . Conjugate synthesis involved the modification of transferrin and polycations with bifunctional reagents or, in a more specific manner, a ligation through the transferrin carbohydrate moiety [148] . Optimized delivery of DNA occurred with Tf-polycation to DNA ratios that resulted in electroneutrality. It was demonstrated that the presence of excess free transferrin interferes with DNA uptake [146] and that up-regulation of the transferrin receptor by agents like desferrioxamine increases the subsequent gene expression in K562 cells [147] . Using fluorescence-labeled DNA complexes, endocytosis into internal vesicles of more than 95% of the cells was found in the erythroid cells [146] and also a series of other cell lines [our unpublished results]. In many cell types the gene expression was strongly dependent on the presence of the lysosomatropic agent chloroquine during the transfection (see section below). Initially the polycations were considered to be simply DNA-attachment elements. A novel type of transferrin conjugate was prepared that contains the DNA-intercalator ethidium homodimer instead of polylysine as the DNA-binding group [148] . With these conjugates, however, the efficiencies of receptor-mediated gene delivery were considerably lower compared to the use of optimized Tf-polylysine-DNA complexes. Electron microscopy studies with the most efficient polylysine conjugates have shown that DNA, upon complex formation, is condensed to small toroid structures with a size of 80-100 nm [149] . The condensation of the DNA complexes by polylysine and other polycations strongly correlated with high gene transfer activity [149] . This led to the conclusion that packaging of DNA into particles of dimensions similar to the size of coated pits is important for efficient receptor-mediated endocytosis of the complex. Consistent with this hypothesis, the DNA delivery with Tfmthidium homodimer was drastically improved by condensation of the DNA with additional unmodified polylysine.
Intracellular fate and expression of gene constructs in various cell types
Although there is clear evidence regarding the first steps of DNA uptake (i.e. receptor binding and endocytosis into internal vesicles), subsequent steps by which the DNA is transported to the nucleus of the cell are still unclear. There is accumulating evidence that the majority of Tf-DNA complexes are not recycled to the cell surface but are delivered into lysosomal and other internal compartments, where they can be still detected more than 1 day after transfection [our unpublished results]. Nevertheless, in many cell lines, at least some of the DNA is transported to the nucleus, as expression of marker genes contained on up to 15-kb large DNA plasmids has been demonstrated [150] . LacZ gene transfer into K562 cells (in the presence of chloroquine) resulted in a particularly high expression of 13-galactosidase between day 2 and day 9 post-transfection, showing that more than 90% of the cells expressed the gene. The Tfpolylysine method appeared to be particularly gentle, with no cytotoxic effects observed. Also 0.5-1% stable G418-resistant colonies were obtained upon transfection of K562 cells [150] and other cell lines such as the H9 T-cell line [Matt Cotten, unpublished results] . A series of TfR-bearing cells has been successfully transfected with T~ polylysine-DNA complexes, but with significantly lower expression levels than in K562 or HD3 erythroid cells; these include [150] human HeLa, HepG2, H9, Ewing's sarcoma EW-2 cells, murine NIH 3T3 and hamster CHO cells, COS cells, chicken EGFR-myb transformed erythroblasts, REV-NPB4 lymphoblasts and normal bone marrow cells. The method also has been applied for gene transfer to respiratory epithelial cells [151] . Calabretta and colleagues have described the use of Tf-polylysine for enhanced delivery of c-myb antisense oligonucleotides to HL-60 leukemic cells [152] .
Similar receptor-mediated gene transfer systems have been developed using ligands other than transferrin: the viral protein HIV gpl20; antibodies against CD4 or CD7 for the targeting of Tcells [150] ; asialoglycoprotein [138] [139] [140] [141] [142] [143] or synthetic galactose-containing peptides [153] for the targeting of hepatocytes via the asialoglycoprotein receptor; insulin [137, 154] ; anti-thrombomodulin antibody [155] [156] for lung targeting, lectins such as WGA [157] and additional ligands.
Enhancement of delivery by endosome-disruptive viruses or peptides
Exit from endosomes as the limiting step of delivery
Although Tf-polycation-DNA complexes provide satisfying levels of gene expression in several TfR-rich cell lines, in many other cell types the expression levels have been very low. Certainly there was no clear correlation between TfR levels and success of gene transfer; it became apparent that it was not receptor binding and uptake into endosomes, but later steps in the receptormediated gene delivery process that were limiting factors. In many cell types the reporter gene was expressed only in a small fraction (less than 1%) of cells, although the DNA had been delivered into the vesicular system of most cells. The accumulation of the complexes in internal vesicles seemed to be a major block on the pathway and strategies had to be developed to prevent degradation of the DNA in lysosomal compartments and promote transport to the nucleus.
In the natural context, after endocytosis many non-recycling ligands are targeted to lysosomes and degraded by hydrolytic enzymes. A related process has been described for gene transfer by calcium phosphate precipitation, where over 50% of delivered DNA is found degraded in lysosomes [158] . A measure to block degradation of material in lysosomes involves the use of lysosomotropic agents such as chloroquine that might prevent acidification of lysosomes and accompanying activation of lysosomal hydrolytic enzymes. Including chloroquine during the first 4 hours of transfection enhances the expression levels in many gene transfer experiments mediated by Tf-conjugates [146, 147] or other ligand-conjugates [153] . The action of chloroquine may be more complex. Other lysosomotropic substances that interfere with activation of lysosomal enzymes were found to be ineffective [150] . Surprisingly, monensin which promotes TfR-mediated toxin delivery (see Sect. 3.1) antagonizes the action of chloroquine in K562 cells. It also appears that incorporation of the metabolically stable poly(D)lysine, that might be predicted to protect delivered DNA, did not influence or improve gene transfer efficiency [149; our unpublished observations]. Based on these and further findings (see below), it was concluded that a major bottleneck of gene transfer is not the degradation but the release of DNA complexes from endosomes to the cytoplasm. The spectacular enhancement of gene transfer by chloroquine in K562 cells was then explained by a second mechanism of this agent [159] . In K562 cells the endosomes reach an unusually low pH due to a defect in Na + ,K + -ATPase regulation [160] . Presumably, K562 endosomes accumulate exceptionally high amounts of the weak base chloroquine that may act osmotically [161] , vacuolizing and destabilizing the endosomes. This also may explain the antagonistic effect of monensin, an ionophore that prevents the build-up of a pH gradient by a different, non-vacuolizing mechanism.
Viral particles promote exit from endosomes
The Tf-polylysine-DNA complexes share similarities with natural viruses both in size and in certain entry functions. Similar to viruses, which compact their nucleic acid genome with core proteins, the DNA is condensed with polylysine. The complexes are coated with Tf as a ligand for attachment to the cell and for receptor-mediated endocytosis, which resembles the entry process of viruses such as adenoviruses, influenza virus or the picornaviruses. The DNA complexes, however, still lack a further important function of viral entry: the release of the viral genome from endosomes into the cytoplasm. The normal endosomal acidification process specifically activates viral coat protein domains that trigger disruption of the endosomal membrane, in the case of membranefree viruses such as adenoviruses [77, 78] , or the fusion of the viral membrane with endosomal membranes in the case of enveloped viruses such as influenza virus [162] .
In addition, the viral entry functions have been found to influence the intracellular delivery of other macromolecules [163] [164] [165] . Several groups observed that the presence of adenoviruses during receptor-mediated uptake of macromolecules such as Pseudomonas exotoxin conjugates targeted to the EGF receptor [77, 78] or TfR [49] enhanced the entry of the macromolecules into the cell cytoplasm. The question was raised whether the endosome-disruption activity of adenoviruses might be used to enhance escape of the larger Tf-polylysin~DNA particles from vesicular compartments. It was found that the replication-defective adenovirus d1312 augmented the levels of Tf-mediated gene expression in a dose-dependent manner up to more than 2000-fold in many cell lines that express high levels of both adenovirus and TfR, such as HeLa, KB or CFT1 cells [166] . Because only the endosome-disrupting activity of the virus protein capsid is thought to be required, it was possible to inactivate the viral genome by irradiation with short-wave UV or with long-wave UV plus psoralen without losing the enhancing activity on DNA gene transfer [167] . In contrast to recombinant adenoviral vectors, the DNA to be delivered is not part of the viral genome which allows flexibility in both size and sequence of the delivered DNA, demonstrated in examples such as the functional delivery of a 48-kb luciferase-encoding cosmid [167] .
For efficient gene delivery, co-localization of both adenovirus and Tf-polylysine-DNA complexes in the same endosome is essential. Enhancement of Tf-mediated gene transfer, therefore, is only possible if relatively high levels of virus (up to more than 10 000 particles/cell) are applied and if cells express sufficient levels of adenovirus (AdV) receptor. For instance, in K562 cells where in the presence of chloroquine Tf-mediated gene transfer worked very efficiently (see above) replacement of chloroquine by free adenovirus particles could not generate significant levels of gene expression. These drawbacks have been overcome by physically linking the adenovirus to the DNA complex [159 168169 ]. For this purpose replication-defective adenoviruses were provided with DNA-binding polylysine tails, either by direct covalent linkage through enzymatic coupling [159] , by biochemical linkage between biotinylated viruses and streptavidin-polylysine [168] , or by immunological linkage through adenoviral capsid-specific antibody-polylysine conjugates [169] . The polycation modification of the virus allows ionic binding to the DNA which upon further addition of Tf-polylysine is condensed to yield ternary complexes consisting of both Tf-DNA condensate and adenovirus. Theoretically, these combination complexes (see Fig. 2 A particularly effective alternative to the human AdV was found in the CELO virus, a chicken AdV. This virus displays both an endosomolytic and a gene transfer-enhancing activity similar to the human virus [157] . Because the chicken adenovirus is completely defective in mammalian cells, no cytopathic effects were observed even at high doses of virus that in the case of human E1A-defective adenovirus d1312 lead to toxic effects in several cell lines such as HeLa cells. The inactivity of the chicken virus genome allowed the generation of stably transfected cell clones at the high frequencies of 1-16% of transfected cells.
Enhancement of gene transfer by membranedisruptive peptides
The gene transfer technique described above may become more attractive if virus-free versions can be generated in which the virus particles are replaced by endosome-disruptive proteins or synthetic compounds. The study of the membrane disruption and fusion processes that occur during viral entry and other biologically important membrane events has led to the identification of amphipathic s-helical peptide sequences that are responsible for these membrane processes. The influenza virus hemagglutinin structure is particularly well-studied [162] . The N-terminus of the subunit HA-2 contains a membrane-active peptide sequence which at neutral pH, due to charge repulsions between negatively charged amino acid side-chain carboxylate groups, is prevented from adopting an s-helical conformation. Upon lowering the pH to 5-6 (i.e. endosomal pH) these charges are neutralized by protonation, allowing a transition to an s-helical amphipathic structure which is able to interact and destabilize lipid membranes; in the natural context of influenza virus structure during entry, this is thought to facilitate the fusion of viral and endosomal membrane.
DNA complexes containing transferrin and polylysine have been linked to small synthetic peptides similar to the N-terminal sequence of hemagglutinin HA-2. In the context of the DNA complexes, these peptides have been found to disrupt membranes in a pH-dependent manner and substantially (100-to more than 1000-fold) augment Tf-mediated gene transfer in a series of cell lines [172, 173] . Upon investigation of several related amphipathic peptides it was demonstrated that the peptide-containing complexes with highest, pH-specific activity in liposome and erythrocyte membrane leakage assays also facilitated the most efficient gene transfer in cell culture experiments [172, 180] . These synthetic gene-transfer vehicles (see Fig. 3 ) on the one hand still have 10-to 100-fold lower efficiency than adenovirus-linked DNA complexes; on the other hand, they have been found to be useful for the generation of stably transformed cell lines. Moreover, the synthetic gene transfer system represents an interesting model for the entry of a natural virus, in that the DNA complex contains both Tf as a ligand for endocytosis, and amphipathic peptides as pH-specific endosome disrupting agents. 
Applications and limitations
Gene delivery ex vivo and in vivo
The adenovirus-DNA combination complexes can efficiently deliver genes to a large proportion (10-90%) of primary cells in culture such as endothelial cells [174] , primary fibroblasts, hepatocytes, myoblasts and primary human melanoma cells. However, systemic application of the complexes by tail vein injection in mice or rats was largely unsuccessful due to inactivation of the complexes by blood components [E.W., M.C., and Kurt Zatloukal, unpublished observations] such as the complement system [175, 176] . There was no significant gene expression in any organ, as the majority of complexes were found to be accumulated and presumably degraded by the reticuloendothelial system in liver and spleen. However, employing strategies that reduce the interaction of the complexes with blood (such as local injection into the liver of rats) produce significant luciferase reporter gene expression of 4 x 106 light units/injection site. By clamping off parts of the blood supply during the injection, the mixing of complexes with the blood was significantly slowed, and this improved gene transfer about 10-fold over the standard injection. In tail veins of mice, as a model for in vivo gene transfer to endothelial cells of blood vessels, a similar gene expression was found after local administration with the blood supply clamped off for 20 min [Kurt Zatloukal, E.W., M.C., and Max Birnstiel, unpublished results]. Instillation of the complexes into the lung has resulted in gene transfer to the airway epithelium [177] --however, at levels that are significantly lower that those achieved with recombinant adenovirus vectors.
Applications in gene and cancer therapy
Although receptor-mediated gene transfer in vivo shows clear limitations, delivery into primary cells in culture is very efficient. The high efficiency of delivery to primary cells when the culture environment can be controlled will allow the use of this system for ex vivo treatment of cells harvested from a patient, followed by reimplantation in the patient. For example the clotting factor VIII, deficient in hemophilia A, can be produced by transfected primary fibroblasts at levels more than 10-fold higher than those generated by retroviral vectors [178] . This will facilitate the generation of factor VIII-expressing fibroblast implants for in situ expression of this protein. Other applications include factor VIII or dystrophin (for the correction of muscular dystrophy) expression in myoblasts that will be reimplanted into, and fused with, long-lived muscle tissue.
One exceptionally well-suited application of transferrin receptor-mediated gene delivery will be in the delivery of genes to tumor cells. Part of the success of this approach lies in the rapid proliferation state and therefore high levels of transferrin receptor cycling on tumor cells. One might consider using this system to deliver toxin genes directly into the tumor mass for elimination of these cells. However, the poor survival of our complexes in the bloodstream coupled with the requirement to introduce the gene into every cell in the tumor limits this application.
Recent advances in the understanding of tumor immunology have promoted the idea of a tumor vaccine. The concept is as follows (Fig. 4) : after surgical removal of the tumor from patients with, for example, high-risk primary melanoma, a primary culture is transfected with one or several cytokine genes. X-ray irradiation blocks cell division and the tumor cells, which continue to live and produce cytokine, are applied as vaccine that is expected to induce a systemic immune response against unmodified residual tumor cells that otherwise lead to metastasis. This gene transfer technique seems to be particularly applicable for cytokine gene transfer into tumors because it has several advantages over established protocols, in that a high percentage of primary tumor cells can be targeted, leading to high-level gene expression without the need for selecting transfected clones. Murine M3 melanoma cells transfected with IL-2 or IFN-y gene constructs have been shown to produce high levels of cytokines [179] . In the corresponding mouse model the M-3 tumor cells have been injecte d into the flanks of syngeneic DBA-2 mice; the control tumor cells develop tumors in 6/ 6 animals within 2 weeks, whereas injection of M3 cells transfected with an IL-2 construct have lost their tumorigenicity.
